Log In
Print this Print this

VGX-3400X (formerly VGX-3400)

  Manage Alerts
Collapse Summary General Information
Company Inovio Pharmaceuticals Inc.
DescriptionVaccine consisting of 3 DNA plasmids coded for a consensus hemagglutinin (HA) antigen, a consensus neuraminidase (NEU1; SIAL1) antigen, and a consensus nucleoprotein (NP) fused to the M2e protein
Molecular Target Influenza antigen
Mechanism of ActionVaccine
Therapeutic ModalityPreventive vaccine: DNA vaccine
Latest Stage of DevelopmentPhase I
Standard IndicationInfluenza virus
Indication DetailsProtect against divergent strains of H5N1 influenza; Vaccinate against H1N1 and H5N1 influenza virus; Vaccinate against H5N1 avian influenza virus
Regulatory Designation
PartnerGeneOne Life Science Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today